Karakas, M.; Jarczak, D.; Becker, M.; Roedl, K.; Addo, M.M.; Hein, F.; Bergmann, A.; Zimmermann, J.; Simon, T.-P.; Marx, G.;
et al. Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101). Biomolecules 2020, 10, 1171.
https://doi.org/10.3390/biom10081171
AMA Style
Karakas M, Jarczak D, Becker M, Roedl K, Addo MM, Hein F, Bergmann A, Zimmermann J, Simon T-P, Marx G,
et al. Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101). Biomolecules. 2020; 10(8):1171.
https://doi.org/10.3390/biom10081171
Chicago/Turabian Style
Karakas, Mahir, Dominik Jarczak, Martin Becker, Kevin Roedl, Marylyn M. Addo, Frauke Hein, Andreas Bergmann, Jens Zimmermann, Tim-Philipp Simon, Gernot Marx,
and et al. 2020. "Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101)" Biomolecules 10, no. 8: 1171.
https://doi.org/10.3390/biom10081171
APA Style
Karakas, M., Jarczak, D., Becker, M., Roedl, K., Addo, M. M., Hein, F., Bergmann, A., Zimmermann, J., Simon, T.-P., Marx, G., Lütgehetmann, M., Nierhaus, A., & Kluge, S.
(2020). Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101). Biomolecules, 10(8), 1171.
https://doi.org/10.3390/biom10081171
